NEXTURNBIOSCIENCE Balance Sheet Health
Financial Health criteria checks 2/6
NEXTURNBIOSCIENCE has a total shareholder equity of ₩142.7B and total debt of ₩83.8B, which brings its debt-to-equity ratio to 58.7%. Its total assets and total liabilities are ₩246.6B and ₩103.8B respectively.
Key information
58.7%
Debt to equity ratio
₩83.85b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩36.16b |
| Equity | ₩142.74b |
| Total liabilities | ₩103.84b |
| Total assets | ₩246.59b |
Recent financial health updates
Recent updates
NEXTURNBIOSCIENCE Co., Ltd.'s (KOSDAQ:089140) Shares Climb 33% But Its Business Is Yet to Catch Up
Oct 17
NEXTURNBIOSCIENCE Co., Ltd.'s (KOSDAQ:089140) 33% Price Boost Is Out Of Tune With Revenues
Oct 17Does NEXTURNBIOSCIENCE (KOSDAQ:089140) Have A Healthy Balance Sheet?
Aug 13NEXTURNBIOSCIENCE's (KOSDAQ:089140) Attractive Earnings Are Not All Good News For Shareholders
Mar 28Shareholders Of NexturnLtd (KOSDAQ:089140) Must Be Happy With Their 119% Total Return
Jan 25
Financial Position Analysis
Short Term Liabilities: A089140's short term assets (₩53.9B) exceed its short term liabilities (₩27.9B).
Long Term Liabilities: A089140's short term assets (₩53.9B) do not cover its long term liabilities (₩76.0B).
Debt to Equity History and Analysis
Debt Level: A089140's net debt to equity ratio (33.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if A089140's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: A089140's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if A089140's interest payments on its debt are well covered by EBIT.